Skip to main content
Figure 3 | Journal of Translational Medicine

Figure 3

From: Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer

Figure 3

Sorafenib chemoprevention suppresses tumor angiogenesis, proliferation and induces apoptosis. Prostate tumors from 20-week-old control and sorafenib-treated conditional PTEN-knockout mice well collected and analyzed to measure MVD and proliferation by IHC for the expression of CD31 and PCNA, respectively, apoptosis by the TUNEL assay. (A) Representative CD31 and PCNA immunostained and TUNEL sections of prostate cancer. Positive cells are stained brown. Scale bars represent 100 μm. Plots of MVD (B) and microvessel area (C) expressed as the mean ± s.e. Plots of cancer cell proliferation rates based on PCNA expression (D) and apoptotic rates based on TUNEL positive cells (E). Values are expressed as the mean ± s.e.

Back to article page